Jane Street
RANI icon

Jane Street’s Rani Therapeutics RANI Stock Holding History

Jane Street’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$124K Sell
168,400
-1,151,400
-87% -$1.47M ﹤0.01% 10517
2025
Q4 		$1.78M Buy
+1,319,800
New +$1.99M ﹤0.01% 5029

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Jane Street's RANI Position: Q1 2026 in Review

Jane Street opened a new position in Rani Therapeutics (RANI) in Q1 2026: 165,599 shares worth $122K. The stake represents ﹤0.01% of the portfolio and ranks #10526 among its holdings. This is a return to the name: Jane Street previously reported a position in RANI as recently as Q4 2022.

Jane Street first reported a position in RANI in Q4 2022 and has held it in 2 quarters since. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Jane Street held 165,599 shares of Rani Therapeutics worth $122K as of Q1 2026.
  • Rani Therapeutics was a new Jane Street position in Q1 2026.
  • Rani Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #10526 holding.
  • Jane Street first reported a position in Rani Therapeutics in Q4 2022 and has held it in 2 quarters since.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.